We used Salmonella enteritidis serotype dublin strain SL1438, a nonreverting, aromatic-dependent, histidine-requiring mutant, as a recipient for a recombinant plasmid coding for production of the nontoxic B subunit of the heat-labile Escherichia coli enterotoxin. The S. enteritidis derivative EL23 produced heat-labile enterotoxin subunit B that was indistinguishable from heat-labile enterotoxin subunit B produced by strains of E. coli or Salmonella typhi harboring the same plasmid. Mice immunized orally with strain EL23 developed progressively increasing mucosal and serum antibody responses to both heat-labile enterotoxin subunit B and to the lipopolysaccharide of the vaccine strain. The mucosal antibody response was shown to be immunoglobulin A specific and to be capable of neutralizing the biological activities of both E. coli heat-labile enterotoxin and cholera enterotoxin in vitro.
Cholera occurs when a sufficient number of virulent Vibrio cholerae are ingested, survive passage through the gastric acidity, and interact with and colonize the epithelium of the proximal small bowel. The ensuing extensive diarrhea results from a net outpouring of fluid and electrolytes into the lumen of the bowel in response to a potent exo-enterotoxin produced by these organisms. This enterotoxin (choleragen) is an 84,000-dalton polymeric protein composed of two major, noncovalently associated, immunologically distinct regions or domains (cholera-A and cholera-B) (10) . Of these, the 56,000-dalton B region, or choleragenoid (CT-B), is responsible for binding of the toxin to the host-cell membrane receptor and facilitating penetration of the toxic A region into the cell membrane (9, 11) . The A subunit causes the activation of adenylate cyclase and a subsequent increase in intracellular levels of cyclic AMP. The B subunit is nontoxic and appears to be the immunodominant moiety of the holotoxin (16, 21, 24) .
Recent efforts to develop an effective immunoprophylactic for cholera have employed mutagenesis (2, 12, 17) or recombinant DNA technology (18, 19, 23) to construct strains of V. cholerae genetically incapable of producing the toxic A fragment of the enterotoxin. These genetically altered organisms, which produce CT-B but lack CT-A, have potential for use as live oral vaccines-colonization of the intestinal epithelium with these organisms should elicit a mucosal immune response to the organisms and to CT-B. Some of these strains have provided protection against challenge with V. cholerae, with an overall reduction in the occurrence of diarrhea, but none is completely safe and effective.
We have recently constructed a potential multivalent live oral vaccine for both typhoid fever and the choleraEscherichia coli-related diarrheas (3) utilizing the galactose epimeraseless (gal E) mutant of Salmonella typhi (14) which has been shown to be a safe, effective live oral vaccine for typhoid fever (15, 30) . This strain, S. typhi Ty2la, has previously been used by Formal et al. (13) to construct a potential bivalent dysentery-typhoid vaccine, whose safety * Corresponding author.
and antigenicity have recently been demonstrated in volunteers (28) . We used S. typhi Ty2la as a recipient for a recombinant plasmid containing the gene for production of the nontoxic B subunit of the heat-labile enterotoxin of E. coli (LT-B). This protein shares extensive sequence and immunologic homology with the B subunit of choleragen (4) (5) (6) 8) . The S. typhi derivative strain SE12 was shown to contain a 3.5-kilobase recombinant LT-B plasmid and produced LT-B that possessed no demonstrable biological activity and was structurally and immunologically indistinguishable from the LT-B produced by E. coli strains harboring the same plasmid. The derivative strain was rapidly cleared after intraperitoneal (i.p.) injection into mice, caused no diarrhea or other manifestations when inoculated orally (p.o.) into guinea pigs, and retained the galactose sensitivity characteristic of the parent S. typhi Ty2la. More importantly, mice injected i.p. with SE12 developed a significant antitoxin antibody response which could be specifically boosted with a subsequent injection of either viable organisms or purified LT-B. Although this recombinant strain has potential for use as a live oral multivalent vaccine for both typhoid fever and the cholera-E. coli-related diarrheas in humans, the limited host range of the parent S. typhi precluded a thorough investigation of the full potential of this vaccine candidate or of this approach to development of immunity to enteric pathogens. The ability of this strain when delivered p.o. to induce a specific mucosal antitoxin response cannot be tested except in human volunteers. Fortunately, several of the >1,700 serotypes of Salmonella enteritidis, including serotypes typhimurium and dublin, are able to cause a systemic infection after oral inoculation of mice analogous to that caused by S. typhi in man. Aromatic-dependent mutants of these strains have been shown to protect mice and cattle against subsequent challenge with virulent wild-type Salmonella species (26) .
Because of the relative avirulence of such aromaticdependent mutants, they have been proposed as immunologic vehicles for delivery of antigens from a variety of organisms. Antigens expressed by these strains would pre-sumably be delivered directly to the antibody-forming cells in the gut-associated lymphoid tissues. This should be an effective means of stimulating significant levels of specific mucosal immunoglobulin A (IgA) directed against the carrier strain and the antigen and would stimulate production of serum antibodies as well. The purpose of the current investigation was to determine the efficacy of this mechanism of antigen delivery for production of specific mucosal antitoxin IgA, with delivery of the toxoid antigen to be accomplished by utilizing an avirulent mouse strain of Salmonella sp. This study should provide information about the protective potential of the S. typhi-LT-B hybrid and should also serve as a model system for evaluation of this approach to development of immunity and to the production of mucosal and serum antibodies to a variety of antigens. Antibody assay. Groups of animals were sacrificed at weekly intervals and analyzed by ELISA for production of antibodies to LT-B and, in some cases, to the lipopolysaccharide (LPS) of the vaccine strain. Animals were bled before euthanasia, and sera were stored at -20°C until assayed. The small intestine from the doudenum to the ileal-cecal junction was excised and homogenized in a solution containing 50 mM EDTA and 0.1 mg of soybean trypsin inhibtor (Sigma Chemical Co.) per ml. Samples were homogenized with a Tekmar Tissuemizer, clarified by centrifugation, lyophilized, suspended in 1 ml of TEAN buffer (0.05 M Tris, 0.001 M EDTA, 0.003 M NaN3, 0.2 M NaCl, pH 7.5) (4), dialyzed against TEAN buffer, and stored at -20°C until assayed.
ELISA. Reagents and antisera for the ELISA were obtained from Sigma Chemical Co. Samples for ELISA were serially diluted in phosphate-buffered saline (pH 7. (27) . Serum anti-LT-B or anti-LPS IgG was determined by using rabbit antiserum against mouse IgG conjugated to alkaline phosphatase. Mucosal anti-LT-B or anti-LPS IgA was assayed by using goat antiserum against mouse IgA (alpha-chain specific) followed by rabbit antiserum against goat Purification of cholera toxin, LT, and LT-B. Cholera toxin was prepared as described by Mekalanos et al. (22) . The culture conditions and purification of LT and LT-B were as previously described (6) . Organisms were cultured overnight at 37°C with vigorous aeration and agitation after inoculation with 106 viable bacteria per ml. The bacteria were harvested by centrifugation at 4°C, and the cells were suspended in TEAN buffer and lysed with a French pressure cell. The crude lysate was then dialyzed against TEAN buffer and, after centrifugation, applied directly to columns of Sepharose 4B (Sigma Chemical Co.) equilibrated with TEAN buffer.
Guidelines used for recombiant DNA experiments. The experiments reported here were performed under conditions as specified in the Guidelines for Recombinant DNA Technology published by the National Institutes of Health, Bethesda, Md.
Statistical analysis. The standard error of the mean was calculated for all data, and means of variously immunized groups were compared by the Student t test. Statistical significance was considered to be P -0.05.
RESULTS
Construction of S. enteritidis serotype dublin strain EL23. We have previously described the construction of a plasmid (pJC217) containing the gene for production of LT-B from a human isolate of E. coli H10407. This gene is under control of the lac promoter of plasmid pUC8 (29) and codes for production of LT-B which is structurally identical to the native B subunit when examined by SDS-PAGE, immunologically identical in ELISA and double immunodiffusion, and nontoxic. This is the plasmid that was used to transform S. typhi Ty2la in our previous study (3) . Plasmid DNA from S. typhi SE12 was purified by cesium chloride gradient centrifugation and used to transform S. enteritidis serotype dublin strain SL1438. sistance to ampicillin and assayed by ELISA for production of LT-B. All ampicillin-resistant transformants tested produced LT-B. One such isolate, designated EL23, was selected for further study.
Characterization of S. enteritidis serotype dublin derivative EL23. Strain EL23 was first examined for the presence of plasmid pJC217. Plasmid DNA was prepared from the transformant and examined by agarose gel electrophoresis. Strain EL23 contained a 3.5-kilobase plasmid which, when cut with the restriction endonuclease HindIII yielded the same 2.7-and 0.8-kilobase fragments, representing pUC8 and the LT-B gene, respectively, previously seen with plasmid pJC217 (3) (Fig.1) .
Since the effectiveness of this vaccine is dependent in part upon the structural and immunologic relatedness of LT and choleragen, it was essential that LT-B produced by EL23 be structurally and immunologically identical to LT-B produced by E. coli. LT-B was purified from EL23 by agarose affinity chromatography (6) and examined by SDS-PAGE and ELISA. In SDS-PAGE (Fig. 2) , LT contained two bands, one at ca. 28,000 daltons representing the toxic A subunit (LT-A), and one at ca. 11,500 daltons representing the monomeric from of LT-B (Fig. 2C) . Preparations from both EL23 ( Fig. 2A) and JM83(pJC217) (Fig. 2B ) contained a band corresponding to monomeric LT-B. Neither preparation contained a band corresponding to LT-A. Both preparations were then assayed by ELISA (Fig. 3) , and LT-B produced by EL23 was indistinguishable from LT-B produced by JM83(pJC217). Relative distribution was determined, and LT-B was found to be principally cell associated (94.4%) in strain EL23, a value similar to that observed with E. coli (>96.7%) and with S. typhi derivative SE12 carrying the same plasmid ( Table 1) .
Effect of primary immunization with LT-B. Mice immunized p.o. with LT-B developed progressively increasing levels of serum and mucosal antitoxin antibodies throughout the course of the experiment, 5 weeks post-primary immunization (Fig. 4) . Serum and mucosal antitoxin levels for unimmunized controls were zero (Fig. 4, legend) . Antitoxin serum IgG (Fig. 4A) increased to a maximum of 1,819 ,ug/ml by week 3, leveling off at 1,655 pg/ml by the end of week 5. Similarly, mucosal antitoxin IgA (Fig. 4B) increased to a maximum of 3,439 ng/ml by week 1 and decreased slightly thereafter. The difference between the value observed for mucosal antitoxin IgA at week 1 (3,439 ng/ml) and that at week 5 (2,646 ng/ml) is not statistically significant. (Fig. 5B) . By 11 weeks postprimary immunization there was no significant difference between animals boosted i.p. with LT-B and those receiving a p.o. boost with EL23. Mucosal antitoxin IgA levels after a p.o. boost with LT-B were significantly higher than levels after a p.o. boost with EL23. Although IgA levels after a p.o. boost with LT-B were slightly higher, the differences between i.p. and p.o. boost with LT-B were not significant. Serum antitoxin IgA. All treatment groups reached a maximum level of serum antitoxin IgA at 5 weeks and gradually declined thereafter (Fig. 5C) . By 11 weeks postprimary immunization, serum antitoxin IgA levels were significantly higher in animals boosted i.p. with LT-B over those in animals boosted p.o. with LT-B or those in animals boosted p.o. with EL23. Differences observed between animals boosted p.o. with LT-B and those boosted p.o. with EL23 were not significant.
Mucosal antitoxin IgG.The mucosal antitoxin IgG levels in all treatment groups remained consistently low relative to specific serum antitoxin IgG, probably representing contamination of mucosal preparations during sample processing (Fig. SD) .
Serum anti-LPS IgG. Animals receiving a p.o. boost with EL23 reached maximum serum anti-LPS IgG levels at 8 weeks post-primary immunization, while those receiving p.o. LT-B reached a maximum at 11 weeks (Fig. 6A) . Differences between treatment groups at 11 weeks postprimary immunization were not statistically significant.
Mucosal anti-LPS IgA. Animals receiving a p.o. boost with EL23 reached maximum mucosal anti-LPS IgA levels at 4 weeks post-primary immunization, while animals boosted either i.p or p.o. with LT-B reached a maximum at 8 weeks, (Fig. 6B) . Differences between treatment groups at 11 weeks post-primary immunization were not statistically significant. Therefore, mice receiving strain EL23 p.o. developed progressively increasing mucosal and serum antibody responses to both LT-B and the LPS of the vaccine strain. Boosting i.p. with LT-B gave the highest sustained levels of antitoxin serum IgG and serum IgA, while boosting i.p. or p.o. with LT-B gave equivalent mucosal antitoxin IgA responses.
In vitro toxin neutralization. Samples of mucosa from nonboosted animals from the week 5 sacrifice were pooled and tested for the ability to neutralize the biological activities of cholera toxin and LT in the mouse Y1 adrenal cell assay. a Distribution of LT-B was determined by ELISA as previously described (7) after overnight growth at 37°C on a gyratory shaker. Cells were separated by centrifugation, and supernatants were filter sterilized before testing. Amounts of LT-B in each sample were determined by extrapolation from a standard curve of a known quantity of purified E. coli LT-B. INFECT. IMMUN. Mucosal IgA was capable of completely neutralizing both of the toxins in this system. Mucosal antitoxic IgA titers against LT and CT were 256 and 128, respectively ( Table 2 ).
Determination that neutralization was indeed due to mucosal antitoxic IgA and not to contaminating IgG was accomplished by preincubating the mucosal pool with goat antiserum against mouse IgA, which reduced the neutralizing capacity of the pool, or with rabbit antiserum against mouse IgG, which did not reduce the neutralizing capacity of the pool.
DISCUSSION
A variety of cholera vaccines have been developed since the identification of the causative organism by Koch, the most widely used being parenterally administered killed whole-cell vaccines (21) . Unfortunately, parenterally administered vaccines are not effective at stimulating mucosal antibody production. Since cholera toxin and its B subunit are good mucosal antigens for development of IgA responses, live oral cholera vaccines should be effective at stimulating mucosal antibody production. This has proven to be the case for some of the mutant strains tested, although immunity is primarily antibacterial and none is completely safe and effective. An alternative in the development of live oral vaccines was demonstrated by Formal et al. (13) . In that study, the plasmid responsible for form I antigen synthesis in Shigella sonnei was transferred to galE S. typhi Ty2la, which invades normally but does not survive owing to lack of Vi antigen and to lysis resulting from toxicity of accumu- lated galactose-1-phosphate and UDP-galactose (15) . The transconjugant was shown to express the form I antigen and to provide protection against both Shigella sonnei and S. typhi challenge. In that study, the authors suggested that the galE S. typhi strain or other such attenuated mutants might be effective carriers for other potentially protective antigenic determinants.
We subsequently cloned the gene coding for production of LT-B into Ty2la. The extensive immunologic and sequence homology between LT and cholera toxin (4) (5) (6) 8) made the transformant a potential multivalent live oral vaccine for both typhoid fever and the cholera-E. coli-related diarrheas. The S. typhi derivative SE12 produced LT-B and induced a significant serum antitoxin antibody response when injected parenterally into mice and guinea pigs. We were not, however, able to test the full potential of this strain as a live oral vaccine or of this method of antigen delivery as a means of stimulating mucosal antitoxin antibodies, owing to the limited host range of S. typhi.
We recently obtained an avirulent mouse Salmonella strain capable of producing an infection after oral inoculation of mice analogous to the events associated with oral inoculation of humans with Ty2la. We reasoned that this might provide a suitable model for testing the theory of direct stimulation of the antibody-forming cells in the gutassociated lymphoid tissues with antigen as a means of stimulating significant levels of mucosal antibodies. In this study, S. enteritidis serotype dublin strain SL1438 was transformed with plasmid pJC217, characterized for production of LT-B, and examined for efficacy as an oral vaccine in mice. The derivative strain, designated EL23, produced LT-B that was, by all criteria, identical to the LT-B produced by E. coli or by S. typhi SE12.
Initial priming studies comparing oral immunization with LT-B with oral immunization with strain EL23 showed that immunization with LT-B produced significantly higher levels of antitoxin serum IgG and initally higher levels of antitoxin mucosal secretory IgA. The differences in IgA levels were no longer significant by week 5 and timing on vaccine efficacy, to explore alternatives to Ty2la as a vehicle suitable for administration to humans, and to study the potential role of additional determinants (i.e., cholera somatic antigens) in formulation of an optimum vaccine. This study also provides information relative to develppment of serum antibodies after immunization by this technique. This may have significant implications for others proposing similar approaches with antigens in which a serum antibody response may have a protective role.
The impact of enteric disease on the world's populations is well recognized. A successful immunization program against these organisms would include the following: (i) the most appropriate antigen(s) delivered by the most effective route in a manner designed to stimulate a protective immune response, (ii) development of a minimal number of untoward side effects, and (iii) cost effectiveness. Use of a multivalent live oral vaccine for typhoid fever and cholera-E. coli-related diarrheas should meet all these criteria.
